BrainTransporter™ dramatically improves antibody delivery to the brain November 6, 2024 15:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2024 on November 14 at 9.30 a.m. CET November 6, 2024 08:30 Non Regulatory Read more
Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile October 31, 2024 08:30 Non Regulatory Read more
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer’s Disease October 30, 2024 08:30 Non Regulatory Read more
Lifetime Achievement Award, lecanemab and biomarkers in focus at CTAD October 24, 2024 08:00 Non Regulatory Read more
Eisai will request reconsideration of initial decision for lecanemab in Australia October 17, 2024 01:30 Non Regulatory Read more
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology August 27, 2024 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2024 on August 29 at 9.30 a.m. CET August 19, 2024 08:30 Non Regulatory Read more
Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates August 14, 2024 01:00 Non Regulatory Read more
Long-term treatment data for lecanemab to be presented at AAIC 2024 July 23, 2024 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s first quarter report for January – March 2024 on May 17 at 9:30 a.m. CET May 7, 2024 08:30 Non Regulatory Read more
The Nomination Committee’s proposal for the election of Board members and Chairperson of the Board in BioArctic AB April 16, 2024 15:00 Non Regulatory Read more
BioArctic’s focus on Sustainable Innovation qualifies company for new ESG Responsibility Index at Nasdaq Stockholm April 10, 2024 08:00 Non Regulatory Read more
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer’s European Grand Prix for his contributions to science and treatment of Alzheimer’s disease March 19, 2024 08:00 Non Regulatory Read more
New data on lecanemab presented at the 2024 AD/PD™ congress March 11, 2024 08:00 Non Regulatory Read more
Latest data on lecanemab to be presented at the 2024 AD/PD™ congress February 29, 2024 08:00 Non Regulatory Read more
BioArctic’s CEO Gunilla Osswald Winner of The Arthur D. Little Nordic Life Science Award February 22, 2024 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2023 on February 14 at 9.30 a.m. CET February 5, 2024 08:30 Non Regulatory Read more
